Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical ... with ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig ...

A final decision is expected by Sept. 28, 2025. The FDA filing is supported by data from three late-stage studies — one (HERCULES) in nrSPMS and two (GEMINI 1 and 2) in relapsing MS (RMS).

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link ...

(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and ...

Trethera Corporation ("Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced clinical results from ...